Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

880 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04134559 2026-02-24

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

Phase 2 Recruiting

18 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Phase 2 Recruiting

300 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05185739 2024-12-06

PRIMER-1

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1/2 Recruiting

358 enrolled

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT04770207 2024-08-21

Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs

Phase 2 Recruiting

100 enrolled

GastrointestinalThoracic

Carcinoma, Hepatocellular, Lung Neoplasms

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Phase 2 Recruiting

90 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase 2/3 Recruiting

200 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06389422 2024-04-29

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

PSI-Immune

PNeoVCA

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

PRIMER-1

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis